Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
anonusers Placed a 'Buy' Sentiment on YRCW14 hours ago
anonusers Placed a 'Buy' Sentiment on TLND1 day ago
anonusers Placed a 'Buy' Sentiment on AMRN6 days ago
coversinplay Followed high-beta-volatile-stocksMore than a week ago
coversinplay Followed current-movers-declinersMore than a week ago
coversinplay Followed buy-to-sell-today-positiveMore than a week ago
russurban Placed a 'Buy' Sentiment on VXRTMore than a week ago
russurban Followed jennsellsMore than a week ago
russurban Followed SONMMore than a week ago
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  UNVC  •  VXRT  •  OSTK  •  NFLX  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  Reserve Investor Relations Services for OTC Stocks at

July 6, 2004 Stock Pick: Biophan Technologies, Inc. (BIPH)

Stock Price: $1.00

Biophan Technologies, Inc. develops and markets biomedical devices that allow for cardiac pacemakers, surgical and diagnostic tools to become safe and compatible with MRI equipment. An MRI is an advanced X-Ray machine used to diagnose problems within the brain and/or body. The company currently holds nine patents with over fifty pending approval in the areas of nanomagnetic particle coatings, radio frequency filters, polymer composites, and photonics.

The company is currently in research and development with Boston Scientific. Boston Scientific will have the first right to negotiate the licensing of Biophan technologies that come out of the joint venture between the two companies. The marketing strength of Boston Scientific will greatly enhance the future success of Biophan’s products.

The Cohen Independent Research Group recently provided a comprehensive research report on BIPH. The Group placed a low-end price target of $4.46 and high-end of $10.59 on BIPH shares. For the in-depth report.

The CEO has reiterated that they plan on listing on a major US exchange by the end of the year. The issued share count will not go over 80 million shares in the near future. With only 67 million shares outstanding there is room for additional financing to occur.

Untitled Document